GCP
BHVN

GSA Capital Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

GSA Capital Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,122
Closed -$321K – 2050
2022
Q3 		$321K Buy
+2,122
New +$314K 0.04% 889

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

GSA Capital Partners's BHVN Position: Q4 2022 in Review

GSA Capital Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,122 shares — an estimated $321K sold.

GSA Capital Partners first reported a position in BHVN in Q3 2022 and held it in 1 quarter. The position peaked at $321K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • GSA Capital Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 2,122 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $321K.
  • GSA Capital Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022 and held it in 1 quarter.
  • GSA Capital Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $321K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.